Before COVID-19, scientists had spent years investigating the possibility of using mRNA as a vaccination method — as a way to transmit instructions on how to produce germ-fighting antibodies directly into patients’ cell nuclei.
A 2018 study from the University of Cambridge’s PHG Foundation suggested that mRNA vaccines could be faster, cheaper, and safer to produce than conventional vaccines, which inject weakened forms of a germ for patients’ immune systems to use as target practice.
But until COVID-19, mRNA medicine was a completely speculative technology; the Food and Drug Administration (FDA) had never previously approved any mRNA-based vaccine or treatment.
The approval and successful rollout of the Moderna and Pfizer vaccines — both of which are mRNA-based — is a watershed moment for the technology, and could bring many more mRNA-based vaccines and treatments to market behind it.
Custom antibody production — although not quite as new as mRNA medicine — is another emerging medical technology that has seen its development accelerate during COVID-19.
Fortune Business Insights estimates that the antibody industry will grow at a compound annualized growth rate (CAGR) of 14% through 2027 — a significantly faster growth rate than the firm’s pre-COVID projections.
And the rapid rise of investor interest in antibody production is striking. Regeneron Pharmaceuticals saw its share price climb 10% during the week when its custom COVID-19 antibody cocktail was given to President Trump during his illness.
But this is just one past example of how COVID-19 has directed investors’ attention toward new biotechnologies. The three stocks we’re profiling below are each developing new vaccines and therapies based on scientific techniques pioneered during the pandemic — but none have caught the attention of rank-and-file investors, yet…
ImmunoPrecise (NASDAQ: IPA)
Founded in 1989 and based in Victoria, British Columbia, ImmunoPrecise is a leading developer and manufacturer of custom antibodies.
CEO Jennifer Bath recently explained on Fox Business Network that the company is currently producing custom antibody cocktails for all of the documented variants of COVID-19.